CHAD Therapeutics Reports Third-Quarter Results.Business Editors CHATSWORTH Chatsworth, estate, Derbyshire, central England, near Chesterfield. It is the seat of the dukes of Devonshire. Begun in 1552, the present Classical-style Chatsworth House was rebuilt in 1686. , Calif.--(BUSINESS WIRE)--Feb. 9, 2001 CHAD Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. Inc. (AMEX AMEX See: American Stock Exchange :CTU CTU Colorado Technical University CTU Czech Technical University in Prague CTU Counter Terrorist Unit CTU Clinical Trials Unit CTU Catholic Theological Union CTU Chicago Teachers Union CTU Computer Training Unit CTU Control Unit ), producer and distributor of oxygen conserving con·serve v. con·served, con·serv·ing, con·serves v.tr. 1. a. To protect from loss or harm; preserve: devices and oxygen systems used by pulmonary pulmonary /pul·mo·nary/ (pool´mo-nar?e) 1. pertaining to the lungs. 2. pertaining to the pulmonary artery. pul·mo·nar·y adj. Of, relating to, or affecting the lungs. patients who need supplementary oxygen, today announced operating results for the third quarter ended Dec. 31, 2000. Sales for the quarter were $2,757,000, a decrease of $202,000, or 7% from the same quarter last year. For the nine months ended Dec. 31, sales declined to $8,856,000, down 12% from the same period last year. The company's net loss for the third quarter was $856,000 ($0.09 per share) compared with $683,000 ($0.07 per share) for the same quarter last year. For the nine months ended Dec. 31, the net loss was $2,261,000 ($0.23 per share) compared with $1,271,000 ($0.13 per share) for the same period last year. Thomas (language) Thomas - A language compatible with the language Dylan(TM). Thomas is NOT Dylan(TM). The first public release of a translator to Scheme by Matt Birkholz, Jim Miller, and Ron Weiss, written at Digital Equipment Corporation's Cambridge Research Laboratory runs E. Jones, chief executive officer, stated: "Although total sales dollars declined in the current quarter as compared to the prior year's quarter, domestic unit sales unit sales Sales measured in terms of physical units rather than dollars. Unit sales data are often used by financial analysts when evaluating the health of a company. of the OXYMATIC(R) conserver con·serve v. con·served, con·serv·ing, con·serves v.tr. 1. a. To protect from loss or harm; preserve: increased by 24% during the same period. Sales in the conserver line continue to be affected by competitive factors, which has resulted in price reductions and corresponding gross margin declines. "However, in July 2000 we introduced the new OXYMATIC Model 401 conserver and this product has enabled the company to begin to regain market share in the conserver market. In addition, the company has recently introduced the newest addition in our line of oxygen conservers, the OXYMATIC Model 411 conserver. "This product utilizes every breath delivery technology and is designed to give homecare providers and patients the widest choice available from a single company of conservers to suit individual needs and preferences. Initial shipments of the OXYMATIC Model 411 conserver were made in January 2001, and the initial market reception along with the success to date of the Model 401 conserver is confirming the roles of these products as key elements of CHAD's strategic plan to regain market share in the conserver market." Jones further stated: "While we are making some progress on increasing market penetration Noun 1. market penetration - the extent to which a product is recognized and bought by customers in a particular market penetration - the act of entering into or through something; "the penetration of upper management by women" of the TOTAL O2(R) Delivery System in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , international sales have started to make a significant contribution. The international activity has been led by sales in Europe where the company's distributor recently introduced this product. Increased market penetration in the domestic market will depend, to some extent, on projects underway to reduce the unit cost of this product and thereby lower its selling price." The foregoing statements regarding prospects for the TOTAL O2 system, OXYMATIC Model 401 and 411 conservers and products under development are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve certain risks and uncertainties. The success of these products will depend upon, among other things, the health-care community's perception of each product's capabilities and benefits, the degree of acceptance the products achieve among homecare providers and patients and, with respect to products under development, obtaining timely regulatory approval.
CHAD THERAPEUTICS INC.
Selected Financial Data
December 31, 2000
Nine Months Ended Three Months Ended
December 31, December 31,
2000 1999 2000 1999
Net Sales $8,856,000 $10,013,000 $2,757,000 $2,959,000
Interest Income 67,000 24,000 28,000 17,000
Earnings (Loss) Before
Income Taxes (2,261,000) (1,178,000) (856,000) (468,000)
Net Earnings (Loss) (2,261,000) (1,271,000) (856,000) (683,000)
Basic Earnings (Loss)
Per Share (.23) (.13) (.09) (.07)
Diluted Earnings (Loss)
Per Share (.23) (.13) (.09) (.07)
Balance As of
December 31,
2000 1999
Cash & Marketable Securities $ 1,355,000 $ 1,930,000
Total Assets 11,356,000 14,722,000
Shareholders' Equity $ 9,957,000 $13,441,000
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion